Cell and gene therapy: Global Innovation and Opportunity


Hailed as a revolution in the treatment of many diseases, cell and gene therapy (CGT) is the fastest growing area of therapeutics.

2023 was a record year for CGTs, with seven new CGTs approved by the US Food and Drug Administration (FDA) across a variety of different disease areas. Perhaps most significantly, Casgevy (or exa-cel) from Vertex Pharmaceuticals and CRISPR Therapeutics, was approved to treat sickle cell disease and became the first gene therapy that uses CRISPR gene editing.

2024 is potentially shaping up to break this record. Three CGTs had already been approved by the FDA by mid-March, with another three expected later in in 2024, and an additional three more possible.

Download this In Focus eReport to gain a full understanding of the current market for CGTs and the areas of greatest commercial potential for the future.

Learn more about:

  • The global market for cell and gene therapies, predictions for thefuture and the latest developments driving the sector
  • How allogeneic CAR-T therapies could democratise access to these cancer treatments
  • The latest breakthroughs in clinical research in both cell and gene therapies
  • Which diseases CGTs could treat in the future

Download now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free